Introduction. The adoption of precision medicine (PM) has been limited in practice to date, and yet its promise has attracted research investments. Developing foundational economic approaches for directing proper use of PM and stimulating growth in this area from multiple perspectives is thus quite timely. Methods. Building on our previously developed expected value of individualized care (EVIC) framework, we conceptualize new decision-relevant metrics to better understand and forecast the expected value of PM. Several aspects of behavior at the patient, physician, and payer levels are considered that can inform the rate and manner in which PM innovations diffuse throughout the relevant population. We illustrate this framework and the methods using a retrospective evaluation of the use of OncotypeDx genomic test among breast cancer patients. Results. The enriched metrics can help inform many facets of PM decision making, such as evaluating alternative
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In this article, building on our previously developed expected value of individualized care (EVIC) conceptual framework, 22 we develop a conceptual framework to better understand the value of PM and optimal research investment opportunities in PM. We enrich the theory underlying EVIC and develop parallel methods to convert it into a positive tool for forecasting the expected value of precision medicine by incorporating several aspects of behavior at the patient, physician, and payer levels, which culminate in the way in which PM innovations diffuse through the relevant population and over time. Our methods highlight that the traditional approach (e.g., cost-effectiveness) to looking at the value of genomic test, even from an extra-welfarist social insurer's perspective, may be misleading if the subsequent influence of the social insurer's decisions on individual-level decision making is not accounted for. We illustrate the use of these methods and the implications for coverage by an insurer and research investments by a manufacturer using an empirical case study of using a genomic test (OncotypeDx) to choose the use of chemotherapy in breast cancer patients. Discussion follows, including recommendation of future research that can help estimate the parameters in the new EVIC metrics.
EXPECTED VALUE OF INDIVIDUALIZED CARE (EVIC)
The concept of EVIC was developed by Basu and Meltzer. 22 Inherently, it compares 2 approaches to patient management: all patients receive the same treatment (paternalistic model) v. each patient receives the treatment that leads to optimal outcomes for individual patients (individualized model). Since prescribing a perfect individualizing mechanism or test could also be seen as ''paternalistic,'' we drop this distinction and classify the 2 approaches to patient management as the nonuse (homogeneous care) v. use (individualized care) of an individualizing mechanism or PM. The assumptions that are inherent to both the homogeneous care model and the individualized care model are as follows: Under assumptions 1 to 7, the EVIC is then given by (see Basu and Meltzer 22 and the online Appendix for details)
where NHB are evaluated at the social threshold for willingness to pay for B. EVIC represents, from a societal perspective, a normative upper bound on the value of research for developing a perfect PM test that helps to identify individualized information about each patient to the physician so that she can choose the best treatment for each patient. Naturally, EVIC, as expressed in (1), is greater than zero. EVIC from a societal perspective, accounting for the cost of the PM test, would be given as
where C PM is the price of the PM test.
To make these calculations more decision relevant, we evaluate the expected value of individualized care from a social insurer's point of view, who may not share the same perspective as an allencompassing social planner but rather evaluates costs and benefits that fall under her jurisdiction. A social insurer covers patients throughout their lifetime. We do so to tie potential patient-physician behaviors to calculate the potential returns to decision making by an insurer and relate it to the potential for commercial success for a manufacturer of a PM test.
Under assumptions 1 to 7, the EVIC from a social insurer's point of view, who is interested in maximizing NHB but also bears the total costs of the PM test but not the cost of treatments, is given as
where C k reflects the costs of treatments corresponding to the one that produces the maximum net health benefits for level of u (i.e., C k 5 C argmax j NHBðuÞ ), while C k 0 reflects the cost of the treatment that corresponds to the maximum net health benefits on average.
EXTENSIONS TO THE ORIGINAL EVIC FRAMEWORK
In what follows, we keep assumptions 1 and 2 fixed throughout this article as they represent fundamental structural assumptions of the EVIC framework. Relaxing these assumptions is relegated to future work. We now explore how EVIC Insurer is altered as we start relaxing the other assumptions implicit in the EVIC framework to create a tool that can be used to inform prioritization decisions for PM in practical settings.
Potential Uptake of Treatments When Patients Bear the Full Costs of Treatments (Relax Assumption 4)
If patients bear the costs of treatment, the price elasticity of demand, driven by the income distribution in the population, will bring down the use of the treatment even if its expected NHB or individualized NHB is the highest among alternatives. With assumption 4 relaxed, the EVIC Insurer will be altered by a new factor k ( Table 1 , row 1, equation 4), where (1 -k) indicates a factor by which EVIC Insurer in (1) is altered because of the probability that a treatment may not be used even if a physician recommends the treatment. In our breast cancer example, the use of chemotherapy will fall, irrespective of the Treatment uptake reduces as patient bears the full costs of treatments (4)
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presence of a diagnostic test, if patients bear the full cost of the drugs.
Treatments Are Covered in Full by the Insurer (Relax Assumption 5)
In this case, 2 things happen. First, patient choice of treatments is no longer influenced by the costs of treatment as the demand price to the patients is zero. Therefore, factor k drops out of equation (4) . Second, the objective function that the physician is trying to maximize (i.e., patient welfare) may deviate from the social welfare function that a social planner/ insurer may try to maximize. For example, the insurer wants to maximize average NHB in the population but the physician may act to maximize only benefits B since patients do not bear the costs of treatment any longer. Therefore, EVIC Insurer should account for the implicit physician/patient behavior that is induced by covering treatments and is shown in Table 1 (row 2, equation 5), where C k reflects the costs of treatments corresponding to the one that produces the maximum benefits for level of u, while C k 0 reflects the cost of the treatment that corresponds to the maximum benefits on average. For example, if breast cancer patients do not bear the costs of chemotherapy, physicians may prescribe treatment only based on expected life years or quality-adjusted life years (QALYs), although the insurer would bear the costs of those choices.
EVIC Insurer in (5) will be lower than EVIC Insurer in (2) due to the welfare loss from moral hazard induced by covering treatments. In fact, in certain circumstances, it is possible that the EVIC Insurer in (5) can be negative. 22 However, the change in magnitude for EVIC in (5) compared to EVIC in (4) is ambiguous. That is by removing the patient's sensitivity to treatment costs, EVIC in (5) could be greater as the PM test may be able to induce enough benefits to recuperate the costs of treatment now borne by the insurer. Henceforth, we will continue to assume that both treatments and PM are covered in full by the insurer, as this is typically the case in most US settings. One can easily use this formulation to capture differential copay or coinsurance for the treatments.
Imperfect PM Test (Relax Assumption 6)
In this case, say the new PM test has a sensitivity of S n and a specificity of S p , where S n \ 1 and S p \ 1. Consequently, the test may lead a physician to choose a treatment for an individual patient that does not produce the maximum benefits for that patient, that is, max j B(u) | PM \ max j B(u) for some patients.
Interestingly, from the insurer's point of view, EVIC follows equation (6) in Table 1 (row 3) , which means that EVIC Insurer can be higher with an imperfect test (as in (6)) over a perfect test (as in (5)) because the imperfection leads to the reduction in inefficiency that occurs due to the failure by physicians to internalize the costs of treatments while making treatment decisions for their patients. While this is not a general result, it illustrates that such an outcome is possible. For example, an imperfect diagnostic test in breast cancer can reduce the inefficiencies generated due to the moral hazard of insurance coverage of chemotherapy.
Uncertain PM Test (Relax Assumption 6)
In reality, not only are PM tests less than perfect, but their properties are often estimated from samples with considerable uncertainty. (For example, say the new PM test has an expected sensitivity of S n ; Beta(â n ;b n ) and an expected specificity of S p ; Beta(â p ;b p ), where the Beta distribution was chosen because S n , S p 2 ð0; 1Þ and the^indicates that the parameters of this distribution were estimated from some samples.) In this case, both the imperfect and the uncertain information on the test may lead a physician to choose a treatment for an individual patient that does not produce the maximum benefits for that patient, that is, max j B(u) | PM \ max j B(u) for some patients. Therefore, EVIC Insurer will have the same expression as in (6) .
The EVIC framework can be directly linked to the other concepts of value of information (e.g., expected value of perfect information [EVPI] and the expected value of sample information [EVSI]) that are used to prioritize and value future research that aims to estimate the test properties with greater precision. 23, 24 In our formulation: Note that the difference between these formulations of EVPI and EVSI and those that are typically reported in the literature is that our formulation accounts for the contextual behavior of patients in choosing treatments given their coverage scenarios in establishing the value of research on PM properties. This becomes an important consideration given our next section.
EVIC with Passive Personalization (PPM) (Relax Assumption 3)
Homogeneous care model leads to the same treatment choice for all patients (either based on maximum expected benefits or net health benefits) as u i is unobserved to the physician. However, in clinical practice, there is existence of passive personalization (PPM). 25, 26 PPM involves a passive approach to personalization where, in the absence of an explicit PM test, patients and physicians ''learn by doing'' mostly because of the repeated use of similar products on similar patients or employ other readily available prediction algorithms. Thus, PPM signifies relaxing assumption 3, where physicians obtain some knowledge about u and prescribe treatments accordingly. Any PPM mechanism is deemed to be successful from a patient perspective if patients receiving the new treatment are benefiting more than the average patient. [25] [26] [27] Therefore, an important aspect of understanding the incremental value of the new PM test is to understand the baseline levels of communication or the passive levels of personalization that exist in clinical practice.
In most cost-effectiveness studies of pharmacogenetic testing strategies, the outcomes under the ''notesting'' comparator are usually informed by efficacy outcomes for the control arm from randomized trials of the targeted pharmaceutical drug or by the uniform use of a specific dose of the drug. [28] [29] [30] To the extent that these comparators differ from the reality of clinical practice, they would tend to produce erroneous evaluations of the PM test without any clear sense of the direction of the biases. Warfarin pharmacogenomic testing to guide initial dosing (to avoid serious bleeding events) is a good case study. Should warfarin pharmacogenomic testing be compared to warfarin dosing based on a patient's demographic and clinical characteristics, which is current clinical standard of care and as was done in a recent randomized controlled trial (RCT), 31 or should it be compared to a single standard dose (not individualized), as was done in another recent RCT? 32 Basing the comparison on the former study is likely to provide a more accurate estimate of the impact of pharmacogenomic testing in this setting.
The presence of PPM is not sufficient to guarantee that the average levels of outcomes will be higher compared to when everyone received the treatment that maximizes average outcome. Thus, PPM can alter the calculation of incremental value between 2 treatments but not necessarily produce higher average results of health compared to the maximum average health produced by a treatment. For that to happen, the sensitivity and specificity of PPM need to be very high.
Consequently, in our current formulation:
depending on the sensitivity and specificity and the uncertainty of PPM. However, even if the extent of PPM is often not known with certainty, Ð max j B u ð ÞjPPM È É pðuÞdu can be known with greater ease as it represents the average level of outcomes observed in current practice. This can be readily used as the baseline level of outcomes in the EVIC calculations, which would then be more relevant for decision making in practice. For example, such EVIC calculations could be used to assess the value of a pragmatic trial to evaluate a new PM technology where the control group mimics current clinical practice.
An EVIC formulation that accounts for PPM in clinical practice is given by equation (9) in Table 1 (row 4). Therefore, consideration of PPM can actually increase the value of a PM test, especially when the first condition in equation (8) holds. Similarly, it would decrease the value of PM test when the last condition in equation (8) holds. In our breast cancer example, the genomic test should not be compared to the chemotherapy use but rather the existing mechanism, such as the National Comprehensive Cancer Network (NCCN) prediction algorithm, of allocating chemotherapy use.
EVIC under Alternative Diffusion/Adoption Trajectories of PM (Relax Assumption 7)
We now arrive at the most critical part of the EVIC formulation that is fundamental to prioritizing investments in PM. As Hall 33 points out, the contribution made by innovation and new technologies to economic growth and welfare is largely determined by the rate and manner by which innovations diffuse throughout the relevant population, a concept largely ignored in the literature on health technology assessments and cost-effectiveness analysis.
Understanding the adoption and uptake of a PM test when one becomes available is critical to understanding the economics of PM innovation and investments.
There is a large literature on technology diffusion. 34, 35 In this section, we plan to relax assumption 7 and develop a reduced-form model for adoption and uptake among physicians and patients. A PM test, when available, is often not universally adopted. Therefore, the population EVIC calculations must change to account for this selective uptake since the basic premise of value of information calculations is that new information is deemed to have value only if it changes behavior. The expected population outcomes with a PM test at any point in time is a weighted average of outcomes among those who use the PM test and those who do not. Denoting the proportion of the eligible population receiving the PM test as Pr(PM), we have equation (10) in Table 1 , row 5. In the absence of any information about the selective uptake of a PM test, a nonselective uptake can be assumed (which means that the max j B u ð ÞjPM È É in equation 10 is the same as max j B u ð ÞjPM È É in equation 9) and therefore the overall EVIC Insurer in equation (9) is merely scaled down in equation (10) using the fraction of the population receiving the PM test.
A framework for prioritization of research and development of PM based on diffusion trajectory and EVIC
Using the refined EVIC framework developed in the last section, we now develop metrics for population-level decision making for an insurer making a coverage decision and also a manufacturer making research and development (R&D) investment decisions for a PM test.
Insurer's Coverage Decision
A social insurer cares both about the clinical benefits and also the budget impact due to the costs of technology. We assume that at any point in time (denoted at t), an insurer determines level of reimbursement (e.g., by making the patient bear a coinsurance rate 1 -r ) for the PM test by maximizing the net present value of the population EVIC Insurer (r). That is,
arg max r n popEVIC Insurer ðrÞ 5 P Á EVICðrÞ Insurer; 0
where d represents a discount rate, P represents the prevalent size of the target population while I represents the time period-specific incident size of the target population over a time horizon T, and following (10) , EVIC Insurer (r) at any point in time is given by
The time period-specific estimate of EVIC Insurer; t is driven by the time period-specific probability of use of the PM test and can be informed by the estimates from the reduced-form models described above. In sum, for an ex ante analysis, these estimates should reflect the anticipated diffusion patterns of the PM test in the population.
Denoting r = 1 to be full coverage and r = 0 as no coverage, the benefit-cost metric for covering a PM test from the insurer's perspective is given as NPV(r = 1) -NPV(r = 0), which implies comparing equation (12) under the alternative diffusion curve of the PM test with and without coverage. Alternative decisions on partial coverage based on instituting copays or a coinsurance rate can also be studied using this framework as predictions of diffusion rates will be altered based on the price elasticity of demand.
PM Test Manufacturer's R&D Investment Decision
A PM test manufacturer's decision to invest in developing a PM would depend on the probability of regulatory success and the extent of commercial success for the PM test as they represent returns to such investments. (A similar metric for a drug manufacturer's incentive for R&D to develop a drug in anticipation of a PM test could also be studied using this framework. We delegate these discussions to future work.) Since only a relatively small number of available companion diagnostic tests have gone through the Food and Drug Administration (FDA) regulatory approval route, we mostly focus on commercial success here. (From a regulator's point of view, it may suffice to approve a test if Pr(EVIC in equation (2) . 0) crosses some predefined threshold. That is, the test is approved for marketing if the probability of positive returns from using the test under an ideal scenario crosses a certain threshold.) These approaches can be easily extended to estimating returns of developing PM used for diagnosis of disease or disease risks.
Commercial success would be based on the revenues the manufacturer can expect through the sales of the PM test. Consequently, expected revenues of a PM test sales are given by
where r*, the coinsurance rate for the PM test that the insurer will find optimal, is a stochastic quantity for the manufacturer at the point of development of the test. Let f(r*) denote the anticipated probability distribution function of r*. One potential method to estimate f(r*) is based on the stochastic values of popEVIC Insurer from (11) under alternate levels of r and then evaluate the Pr(r = r*).
We now illustrate these EVIC concepts by applying them to a case study of OnctotypeDX, a PM test used to identify breast cancer patients for chemotherapy treatment.
EVIC calculations for gene expression profiling for early stage breast cancer
In this section, we illustrate how the EVIC estimates change as we relax some of the assumptions built into the original EVIC framework. We also study the role of diffusion and coverage policies on the expected population value of precision medicine and expected revenues to a manufacturer that may help guide optimal R&D investment decisions for precision medicine.
Our illustration is based on a gene expression test to identify patients with early stage breast cancer who are likely to benefit from adjuvant chemotherapy v. no test. Although adjuvant chemotherapy has been shown to improve recurrence-free and overall survival, 36 it also may cause significant toxicity, sometimes fatal, in patients. Personalization approaches have focused on identifying women who are at a higher risk of distant recurrence and therefore the prime candidates for adjuvant chemotherapy while sparing low-risk patients from these treatments.
In the absence of a genomic test, we start by assuming that there is no other way to personalize chemotherapy. All patients receive chemotherapy. We then relax this assumption based on clinical practice that followed established guidelines for the use of chemotherapy, which includes a form of personalization based on phenotypical prediction rules (e.g., tumor size). A number of cost-effectiveness studies have looked at the net value of specific genomic assays (OncotypeDx, MammaPrint, etc.) compared to phenotype-based prediction models developed by the National Institutes of Health (NIH) or the Adjuvant! Online Program (AOL). [37] [38] [39] [40] We develop a simple Markov simulation model mirroring the features developed in the earliest works 37, 38 and then use it to estimate different value of information metrics over a 20-year horizon under different assumptions. We then use this model to explore the different EVIC concepts discussed in this article. All analyses are conducted from an ''ex ante'' perspective (i.e., before the introduction of the genomic test). reduced depending on the price elasticity of demand for oncology drugs. 41 If patients receive treatment, they may experience fatal toxicity. Otherwise, their true underlying risk status and treatment status determine their lifetime recurrence and death probabilities. Quality of life in each year is determined by their treatment receipt and their recurrence statuses. All parameters in this model are expressed as probability distributions to reflect the uncertainty in their estimates. Table 2 and the Appendix provide a comprehensive list of all parameters. Net monetary benefits are calculated using a $100,000/QALY threshold. 42 
Markov Model for Breast Cancer Treatment

Estimating Diffusion of OncotypeDx
We identify the use of the genomic test (HCPCS: S3854) in the population of lymph node-negative, estrogen receptor-positive female patients with early stage breast (index date identified by the first occurrence of breast cancer ICD-9 code 174.XX or 233 with no such occurrence of these codes in the past 12 months) during 2006 to 2010 within a large integrated health care system. Based on the literature on technology diffusion that puts forth an S-shaped diffusion pattern for most technologies, 34, 35 we model the rate of use of this test, S(t), using a Gompertz functional form that asymptotes to 1:
Let y it denote an indicator for the use of the genomic test by patient i at time t. Therefore, E(y it ) = P(t). Since the genomic test was introduced to the market in 2003 for these patients, we use data corresponding to years 5 to 8 (2008-2011) of the product life cycle. To fit the Gompertz functional form, we fit a complementary log-log link function model to y 0 it = 1 -y it as a function of t (expressed in product life cycle year). Since, 1 -
Alternative Scenarios for EVIC Calculations
Our evaluation of EVIC follows the theory discussed in the previous section and summarized in Table 3 . We start with estimating the simple EVIC concept in (3) with assumptions 1 to 7. All values are expressed in 2003 US dollars (when OncotypeDx was introduced), and QALYs were valued at $100,000/QALYs. In this case, we assume that the comparator is such that no other form of personalization is available (to be relaxed subsequently). We then proceed by relaxing the assumptions as illustrated in Table 3 . For passive personalization, we change the comparator to that where phenotypical predictions are used for personalization of chemotherapy.
To relax assumption 7 on the diffusion of use of the genomic test, we use the estimated diffusion rate of the genetic test from its introduction. Estimates of diffusion patterns beyond the observed life cycle of the test will be based on the Gompertz parametric form and the estimated parameters. Uncertainty in this extrapolation will be accounted for in our probabilistic analyses. The observed coinsurance rate for the genomic test among the beneficiaries of the large integrated health care system in the United States was 20%. If there were a higher coinsurance rate for this genetic test, the use probabilities would have been lower. Similarly, full coverage would have increased the use rates. Note that even though our analyses perspective is ''ex ante,'' we anticipate these estimated diffusion patterns at the point of analyses. Predicting such a diffusion curve prospectively for other genomic tests is discussed in the Conclusions section.
We study the effect of alternative coinsurance rates for the genetic test using the EVIC concept in (12) , which is based on relaxing assumptions 5, 6, 3, and 7, and also introduce coinsurance rate r;Uniform(0,1) for the genomic test. In the absence of a direct estimate of price elastic of demand for a genomic test, we apply an estimate of the arc price elasticity of demand for oncolytic drugs, 41 which reports a 5% increase in use with every 25% decrease in price. Since we observe the diffusion curve, S(t) Obs , at r = 0.20, for any other given level of r and time t in the product life cycle, we shift the estimated empirical use rate for the genomic test downward or upward by multiplying S(t) Obs with (1.05) ((ln(r)/ln(0.75)) -5.5) . (This assumes that if a 25% reduction is applied 10 times to a coinsurance rate of 1, then the coinsurance rate reduces to ;0.075. Therefore, S(t) r=r = S(t) r=0 Á (1.05) ((ln(r)/ln(0.75)) -10) .) To approximate the scenario where r = 0, we consider r = 0.001, which corresponds to an inflation factor of (1.05) ((ln(r)/ln(0.75)) -5.5) = 2.46 to be applied to S(t) Obs , truncating the rates to lie between [0,1]. Next, we study the PopEVIC Insurer (r), expressed in (11) as a function of coinsurance rate r to test whether immediate coverage of the genetic test would have been warranted, which was not done in practice. That is, whether r = 0 produces the maximum PopE-VIC Insurer . Specifically, we calculate population EVIC over 20 annual cohorts of 178,520 patients (based on the 2002 Surveillance, Epidemiology, and End Results [SEER] program), with each cohort followed over 20 years and using a discounting rate of 3%. However, each cohort enters the model at different points on the diffusion curve of the genetic test.
Finally, we study the manufacturer's incentive to develop this genomic test based on anticipation of coverage decision by an insurer. We estimate the Pr(r = r*) for each value of r to reflect the anticipated probability of a given level of coverage. We then estimate the expected revenues for the manufacturer, internalizing this probability distribution. Table 3 presents estimates of EVIC (and corresponding equations) of a genomic test for breast cancer patients as we sequentially relax the assumptions from the original framework.
RESULTS
EVIC Insurer (3) enforces assumptions 1 to 7. It compares the expected value of a perfect genomic test, which is always used, to having no personalization for choosing chemotherapy (which is not covered, yet perfect uptake happens) among breast cancer patients and is estimated to be $23,182 per patient, with an incremental expected benefit of 0.29 QALYs and an expected incremental cost of $6478. Note that this hypothetical scenario is only useful when determining the value of developing a test, when no other test exists.
Potential uptake of treatments when patients bear the full costs of treatments (relax Assumption 4):
Since the patients bear the cost of the chemotherapy treatments, it is natural to imagine that uptake of chemotherapy will not be perfect and will be driven by the price elasticity of demand (relaxing assumption 4). On the genomic test side, this decreases the use of chemotherapy even when prognosis is poor, thereby reducing overall value. On the nopersonalization side, it helps reduce the use of chemotherapy among those who would have been harmed by it without any commensurate benefits, thereby increasing value. Consequently, the net effect is ambiguous, and we find that EVIC Insurer (4) reduces to $4534 as the expected incremental benefits reduce to 0.089 while the expected incremental costs decrease to $4376.
Treatments are covered in full by the insurer (relax assumption 5): When the chemotherapy is also covered fully by insurance (relaxing assumption 5), chemotherapy uptake recovers to baseline levels, but insurers now bear the costs of chemotherapy. EVIC Insurer (5) increases to $42,883 per patient. This is because, in the presence of a perfect personalizing mechanism, promoting the use of chemotherapy when it would really improve outcomes and reduce costs is likely to generate more value.
Imperfect and uncertain PM test (relax assumption 6): Naturally, if that personalizing mechanism were not perfect, then some of the expected value would be lost. For example, when we introduce the test properties of the OncotypeDx test for this genomic test (relaxing assumptions 5 and 6), EVIC Insurer (6) decreases to $15,806 per patient.
EVIC with passive personalization (PPM) (relax assumption 3): Note that until now, the genomic personalization is being compared to no personalization at all. However, clinical practice of prescribing chemotherapy to these patients would follow the standard NCCN guidelines, which tries to personalize treatment decisions based on phenotypical factors. Therefore, when EVIC for the genomic test is evaluated with respect to the baseline levels of personalization that exist in the absence of the genomic test (relax assumptions 5, 6, and 3), EVIC Insurer (9) decreases further to about $13,659.
EVIC under alternative diffusion/adoption trajectories of PM (relax assumption 7): Next, we study how EVIC would change if the uptake of the genomic test occurs only in 50% of the patients (even when the test is fully covered by the insurer), but this constant uptake applies throughout the lifetime of the test. In this case (relaxing assumptions 5, 6, 3, and 7), the insurer loses value as not all patients are getting the test but saves money on the cost of the test. EVIC Insurer (10) reduces to $6830. On top of this, if the insurer places a high coinsurance rate of, say, 50%, it would imply an uptake of the genomic test of only 34% in the population and an EVI-C Insurer (12) of $5315.
Finally, we study how expected diffusion rates (in contrast to a constant uptake rate) would influence the population EVIC calculations. With perfect uptake of the genomic test under full coverage, which corresponds to an EVIC Insurer (9) of about $13,659, the popEVIC Insurer is estimated to be $37.4 billion ( Table 4 ). The corresponding expected revenue for the manufacturer of the test is estimated to be $9.5 billion. However, the empirical diffusion rates observed for the genomic testing among breast cancer patients suggest that diffusion of this technology follows the traditional S-shaped pattern of technology diffusion (Figure 2 ) at the observed coinsurance rate of 20%. By the seventh year since its introduction in 2003, 20% of the targeted breast cancer patients were getting genomic tests.
Our empirical model fits the observed data well (Figure 2 ). This model was used to predict the potential diffusion pattern of this technology over the first 20 years since its introduction under the fixed coinsurance rate of 20% ( Figure 2 ). If diffusion follows this trend, it would take nearly 20 years for uptake of this genetic test to be universal. Incorporating this predicted diffusion pattern produces an estimate of popEVIC Insurer to be only $16.08 billion and the expected revenue for the manufacturer to be $4.25 billion.
Borrowing an estimate of the price elasticity of demand for oncolytic drug and applying it to the demand for the genomic test (along with it uncertainty), we predict that if the genomic test were to be fully covered (coinsurance rate ;0), diffusion of the genomic test would be much faster than what is empirically observed (Figure 2 ). In fact, these estimates (going from 5% in 2005 to 40% in 2009) match closely to recent estimates produced for the youngest patients in Medicare (who bear the closest resemblance to our target population), where the test is fully covered. 43 Based on our predictions, under full coverage, universal uptake of the genomic test could happen by year 8 since its introduction. With such an altered prospect of diffusion, popEVIC Insurer would have increased to $23.9 billion and the expected revenue for the manufacturer to $6.08 billion.
Finally, to understand the expected revenue for the manufacturer when internalizing the stochastic nature of coverage decisions that may follow, we studied the Pr(r = r*) for a range of coinsurance rates starting from r = 1 (no coverage) to r = 0 (full coverage) by increments of 0.10. Since we do not model selective uptake of the test with respect to r (i.e., phenotypically identified high/intermediate-risk patients have the same price elasticity of demand as those identified as low risk), the probability distribution for likelihood of coverage converges to a bimodal distribution at r = 1 with probability 0.44 and r = 0 with probability 0.56. (Ideally, this assumption should be relaxed. However, we do not have any reliable evidence on this issue. Even our overall price elasticity of demand is borrowed. We hope that studying demanded responses such as this in the context of genomic tests would be an active area of future research.) The expected revenue for the manufacturer then is calculated as 0.44 * $3.25 billion 1 0.56 * PM, precision medicine. a Follows observed patterns of uptake (see Figure 2 ). b Over 20 annual cohorts of patients, each cohort followed over 20 years, discounting at 3%. (Table 4) .
Implications for EVIC Calculations
The range of EVIC results shows that decision-relevant metrics for evaluating the value of PM would produce very different assessments of the PM as various behavioral assumptions are relaxed from a traditional economic evaluation framework. For example, traditional cost-effectiveness analyses may not be informative about the range of decisions or policy contexts that are relevant to an insurer. In fact, our results from EVIC based on equation (9), where using the genomic test produces incremental QALYs of 0.09 and a cost savings of about $4000, is identical to results that Hornberger et al. 37 reported using the same assumptions implicit in equation (9) . However, as more behavioral variables, such as diffusion of technology and reimbursement levels, are tested and built into this framework, EVIC estimates change substantially. We believe that these methods can provide decision makers with more decision-relevant tools to explore the value of PM.
DISCUSSION
In summary, we developed an economic framework that captures the value of individualized care derived from genomics-based precision medicine. We started with an established framework, the expected value of individualized care (EVIC), that attempts to estimate the upper bound on the value of a PM test. We showed that many of the assumptions built into such a framework may not be met in practice. We, therefore, started relaxing these assumptions and presented a more decision-relevant metric of valuing PM tests. Application of this framework to the evaluation of the value of OncotypeDx among breast cancer patients replicated some of the prior results of its evaluation but also illustrated that those results are based on assumptions that are often not met in practice. Instead, we showed how incorporating more practical aspects of behavior around PM could lead to drastically different estimates of value. In fact, our framework could be used to directly evaluate alternative reimbursement levels for PM tests, implementation and education programs for physicians and patients, and decisions around research investments by manufacturers and public entities using the metrics expressed in equations (11) and (13) . Although, in this work, we have highlighted the social insurer's and manufacturer's perspectives, similar calculations could be made from the perspective of a payer, clinician, or patient.
There are, however, some limitations in using this framework prospectively in actual decision making, but these can be easily resolved with research that is currently under way. Perhaps the biggest is the need of predicting the diffusion rate of a technology. There is a growing recognition that data on adoption are important to decision makers. 44 In our example, we had the luxury of looking retrospectively and using the observed diffusion rate of OncotypeDx. In prospective settings, decision making on coverage policies or investments needs to happen before observing the diffusion rate. In fact, as we have shown in our example, those diffusion rates would inherently depend on the decision that is being made. These types of exercise are not uncommon in the literature. Most budget impact analyses make an attempt to predict the diffusion rate of a technology. 45 However, more research is needed to better understand adoption decisions of PM by physicians and patients as a function of current evidence and also other idiosyncratic factors. Currently, we are working toward developing such models as part of a large NIH-funded U01 project that, when validated based on its ability to replicate observed diffusion rates of PM, could be incorporated in the EVIC framework to evaluate new PM and identify critical areas for research investment-particularly around evidence generation.
Another limitation of this framework, as illustrated, is the reliance on the net monetary benefits framework to inform decision making. Like costeffectiveness analyses, it should always be pointed out that metrics such as EVIC are meant only to inform decision making, not be the sole guide. The framework can easily be adopted to any objective function that a decision maker chooses to employ. Even when such an objective function is not explicit and multicriteria decision making is employed to making policy decisions, EVIC results can provide an important component of that decision-making process. Furthermore, extensions of this work to evaluate policies such as FDA labeling, direct-to-consumer marketing, integration into clinical practice guidelines and pathways, and incorporation of the potential impact of the Affordable Care Act and future proposed payment models on diffusion of precision medicine technologies are possible and relegated to future work.
With the growth of PM and the increasing investments in this area, as highlighted by President Obama's Precision Medicine Initiative, 14 flexible, decision-relevant metrics that capture the complexity of value and ultimately uptake of PM are needed to help guide research investment and coverage policy decisions. Here, we propose such a framework that could help decision makers in this process.
